

21 May 2025

Solvonis Therapeutics plc
("Solvonis" or the "Company")

Publication of a Prospectus

Solvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that, further to the announcements released by the Company on 15 May 2025 and 16 May 2025, it has today published a prospectus pursuant to the Prospectus Regulation Rules made by the Financial Conduct Authority ("FCA") under Part VI of FSMA (the Financial Services and Markets Act 2000, as amended) (the "**Prospectus**").

The Prospectus, which has been approved by the FCA, will be available shortly on the Company's website at www.solvonis.com and will also be available at the FCA's National Storage Mechanism at: <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets Limited (Joint Broker)

Phil Davies / Patrick Weaver

+44(0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. Solvonis' mission is to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.

www.solvonis.com | [LinkedIn](#) | [X \(formerly Twitter\)](#)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PDIMZGZKDMVGKZM